Aliases & Classifications for Mammographic Density

MalaCards integrated aliases for Mammographic Density:

Name: Mammographic Density 57 73

External Ids:

OMIM 57 607308
UMLS 73 C1846502

Summaries for Mammographic Density

MalaCards based summary : Mammographic Density is related to ductal carcinoma in situ and insulin-like growth factor i. An important gene associated with Mammographic Density is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and superpathway of tryptophan utilization. The drugs Drospirenone and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and bone, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 76 Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast... more...

Description from OMIM: 607308

Related Diseases for Mammographic Density

Diseases related to Mammographic Density via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
# Related Disease Score Top Affiliating Genes
1 ductal carcinoma in situ 30.2 CYP19A1 ESR1 PGR
2 insulin-like growth factor i 30.0 ESR1 IGF1 IGFBP3 PRL
3 breast cancer 29.9 CYP17A1 CYP19A1 CYP1A1 CYP1B1 ESR1 IGF1
4 endometriosis 29.4 CYP19A1 ESR1 HSD17B1 PGR
5 breast disease 28.5 COMT CYP19A1 CYP1A1 CYP1B1 ESR1 IGF1
6 body mass index quantitative trait locus 1 10.3
7 slipped capital femoral epiphysis 10.2 IGF1 IGFBP3
8 secondary adrenal insufficiency 10.2 IGF1 IGFBP3
9 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.2 IGF1 IGFBP3
10 galactorrhea 10.2 IGF1 PRL
11 pituitary infarct 10.2 IGF1 PRL
12 diffuse idiopathic skeletal hyperostosis 10.2 IGF1 IGFBP3
13 pseudohypoparathyroidism, type ia 10.2 IGF1 PRL
14 marasmus 10.2 IGF1 IGFBP3
15 schizophreniform disorder 10.2 COMT PRL
16 empty sella syndrome 10.2 IGF1 PRL
17 isolated growth hormone deficiency, type ib 10.2 IGF1 IGFBP3
18 sheehan syndrome 10.2 IGF1 PRL
19 acid-labile subunit deficiency 10.2 IGF1 IGFBP3
20 traumatic brain injury 10.2 COMT IGF1
21 fetal macrosomia 10.2 IGF1 IGFBP3
22 osteoporosis, juvenile 10.2 IGF1 IGFBP3
23 in situ carcinoma 10.2
24 testicular leydig cell tumor 10.2 CYP17A1 ESR1
25 pseudovaginal perineoscrotal hypospadias 10.1 CYP17A1 IGFBP3
26 vestibular gland benign neoplasm 10.1 ESR1 PGR
27 bartholin's gland adenoma 10.1 ESR1 PGR
28 vulvar syringoma 10.1 ESR1 PGR
29 fibromyalgia 10.1 COMT IGF1 PRL
30 glassy cell carcinoma of the cervix 10.1 ESR1 PGR
31 lung leiomyoma 10.1 ESR1 PGR
32 vulvar benign neoplasm 10.1 ESR1 PGR
33 trigonitis 10.1 ESR1 PGR
34 vulvar leiomyoma 10.1 ESR1 PGR
35 predominantly cortical thymoma 10.1 ESR1 PGR
36 breast medullary carcinoma 10.1 ESR1 PGR
37 breast scirrhous carcinoma 10.1 ESR1 PGR
38 bartholin's gland benign neoplasm 10.1 ESR1 PGR
39 hypothyroidism, congenital, nongoitrous, 4 10.1 IGF1 PRL
40 oncocytic breast carcinoma 10.1 ESR1 PGR
41 progesterone resistance 10.1 ESR1 PGR
42 endometrial squamous cell carcinoma 10.1 ESR1 PGR
43 cribriform carcinoma 10.1 ESR1 PGR
44 hyperpituitarism 10.1 IGF1 IGFBP3 PRL
45 postpartum depression 10.1 COMT ESR1 PRL
46 endometrial disease 10.1 CYP19A1 ESR1
47 endometrial mucinous adenocarcinoma 10.1 ESR1 PGR
48 pituitary adenoma 1, multiple types 10.1 IGF1 IGFBP3 PRL
49 adenoid basal cell carcinoma 10.1 ESR1 PGR
50 breast adenoid cystic carcinoma 10.1 ESR1 PGR

Graphical network of the top 20 diseases related to Mammographic Density:



Diseases related to Mammographic Density

Symptoms & Phenotypes for Mammographic Density

Clinical features from OMIM:

607308

MGI Mouse Phenotypes related to Mammographic Density:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 ESR1
2 behavior/neurological MP:0005386 10.06 COMT CYP17A1 CYP19A1 ESR1 HSD17B1 IGFBP3
3 endocrine/exocrine gland MP:0005379 10.06 COMT CYP19A1 CYP1A1 ESR1 HSD17B1 IGF1
4 cardiovascular system MP:0005385 9.98 COMT CYP19A1 CYP1A1 ESR1 IGF1 IGFBP3
5 adipose tissue MP:0005375 9.88 CYP17A1 CYP19A1 ESR1 IGF1 IGFBP3
6 integument MP:0010771 9.8 CYP19A1 ESR1 IGF1 IGFBP3 PGR PRL
7 liver/biliary system MP:0005370 9.65 CYP19A1 CYP1A1 ESR1 IGFBP3 PRL
8 neoplasm MP:0002006 9.55 CYP1B1 ESR1 IGF1 PGR PRL
9 renal/urinary system MP:0005367 9.43 COMT CYP17A1 CYP19A1 ESR1 IGF1 IGFBP3
10 reproductive system MP:0005389 9.23 COMT CYP17A1 CYP19A1 ESR1 HSD17B1 IGF1

Drugs & Therapeutics for Mammographic Density

Drugs for Mammographic Density (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Drospirenone Approved Phase 4 67392-87-4 68873
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-28-2 5757
3
Polyestradiol phosphate Approved Phase 4,Phase 2,Not Applicable 28014-46-2
4 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 979-32-8
5 Estradiol 3-benzoate Phase 4,Phase 2,Not Applicable
6 Estradiol 17 beta-cypionate Phase 4,Phase 2,Not Applicable
7 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Contraceptive Agents Phase 4,Not Applicable
12 Estrogens, Conjugated (USP) Phase 4,Not Applicable
13
Tamoxifen Approved Phase 3,Phase 2,Not Applicable 10540-29-1 2733526
14
Ethanol Approved Phase 2, Phase 3 64-17-5 702
15
Ergocalciferol Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
16
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
17
2-Phenylethanol Experimental Phase 2, Phase 3 60-12-8 6054
18
Afimoxifene Investigational Phase 3,Phase 2 68392-35-8
19 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
21 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
22 Estrogen Receptor Modulators Phase 3,Phase 2,Not Applicable
23 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
24 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Not Applicable
25 Calciferol Phase 3,Phase 2,Phase 1,Not Applicable
26 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
27 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
28 Vitamin D2 Phase 3,Phase 2,Phase 1,Not Applicable
29 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable
30 Ergocalciferols Phase 3,Phase 2,Phase 1,Not Applicable
31 3,4-dihydroxyphenylethanol Phase 2, Phase 3
32 Antioxidants Phase 2, Phase 3,Phase 1
33 Anti-Infective Agents, Local Phase 2, Phase 3
34 Anti-Infective Agents Phase 2, Phase 3
35 Platelet Aggregation Inhibitors Phase 2, Phase 3,Not Applicable
36 Disinfectants Phase 2, Phase 3
37 Olive Phase 2, Phase 3
38 Protective Agents Phase 2, Phase 3,Phase 1,Not Applicable
39
Fulvestrant Approved, Investigational Phase 2,Not Applicable 129453-61-8 17756771 104741
40
Metformin Approved Phase 2,Phase 1 657-24-9 14219 4091
41
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
42
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
43
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
44
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
45
Lovastatin Approved, Investigational Phase 2 75330-75-5 53232
46
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
47
Tibolone Approved, Investigational Phase 2 5630-53-5
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Not Applicable 77-92-9 311
49
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
50
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Effects of Estradiol on Menopausal Breast Unknown status NCT00785317 Phase 4 Angemin vs Activelle
2 Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial Active, not recruiting NCT01315015 Phase 4
3 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
4 Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women Unknown status NCT00808522 Phase 3 hCG
5 Vitamin D and Breast Cancer Biomarkers in Female Patients Completed NCT01224678 Phase 3
6 Olive Oil for High Risk Breast Cancer Prevention in Women Recruiting NCT02068092 Phase 2, Phase 3 Hydroxytyrosol
7 Trial of 4-OHT Gel in Women Aimed at Reducing Dense Breast Tissue Active, not recruiting NCT03199963 Phase 3 4-OH tamoxifen;Placebo
8 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
9 Statins and Breast Cancer Biomarkers Unknown status NCT00914017 Phase 2 Atorvastatin;Placebo
10 Karma Intervention Study Enrolling by invitation NCT03346200 Phase 2 Tamoxifen Oral Tablet;Placebo Oral Tablet
11 Green Tea and Reduction of Breast Cancer Risk Completed NCT00917735 Phase 2 Green tea extract supplement
12 S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women Terminated NCT00088972 Phase 2 celecoxib
13 Soy Isoflavones and Breast Cancer Risk Reduction Active, not recruiting NCT00204490 Phase 2
14 A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) Terminated NCT00183963 Phase 2 Tamoxifen;Fulvestrant;Fulvestrant
15 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer Completed NCT00073073 Phase 2 Exemestane
16 Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast Recruiting NCT03063619 Phase 2 Afimoxifene
17 Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention Terminated NCT00285857 Phase 2 Lovastatin
18 Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
19 Soy Protein and Breast Cancer Risk Reduction Active, not recruiting NCT00204477 Phase 2
20 Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Active, not recruiting NCT01196936 Phase 2 Tamoxifen Citrate;Placebo
21 Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy Completed NCT00165204 Phase 2 Tibolone
22 Study of Breast Cancer Prevention by Letrozole in High Risk Women Completed NCT00579826 Phase 2 Letrozole;Placebo
23 Protocol for Women at Increased Risk of Developing Breast Cancer Completed NCT00291694 Phase 2 celecoxib
24 Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer Completed NCT00853996 Phase 2 acolbifene hydrochloride
25 Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density Completed NCT03264651 Phase 1 enobosarm
26 A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole Completed NCT03314298 Phase 1 testosterone anastrozole
27 RANKL Inhibition and Breast Tissue Biomarkers Recruiting NCT03629717 Phase 1 Denosumab;Calcium;Vitamin D
28 Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer Completed NCT00976339 Phase 1 Cholecalciferol
29 Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer Active, not recruiting NCT02278965 Phase 1 Metformin;Omega-3 fatty acids
30 Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Recruiting NCT02780401 Phase 1
31 Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
32 Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 Unknown status NCT01666171 metformin hydrochloride
33 Radiologic Evaluation and Breast Density (READ) Unknown status NCT00117663 Not Applicable Cessation of Hormone Replacement Therapy
34 Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast Unknown status NCT00126464 Not Applicable fulvestrant;tamoxifen citrate
35 Brazilian Randomized Study - Impact of MRI for Breast Cancer Unknown status NCT02798796 Not Applicable
36 The Malaysian Soy and Mammographic Density Study Enrolling by invitation NCT03686098 Not Applicable
37 KEEPS Mammographic Density And Breast Health Ancillary Study Completed NCT02524561 Not Applicable CEE pill;Estradiol patch;Active Progesterone
38 Mammographic Density and the Risk of Tumor Recurrence in Asian Women: a Case-control Study Completed NCT02771665
39 VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue Enrolling by invitation NCT02239874 Not Applicable
40 Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk Completed NCT00839696
41 Study Evaluating Changes In Mammographic Breast Density Completed NCT00774267 BZA 20 mg/CE 0.45 mg;BZA 20 mg/CE 0.625 mg;Raloxifene 60 mg;Placebo
42 Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density Completed NCT00470561 Not Applicable Aspirin;Placebo
43 Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502 Recruiting NCT03609021
44 Genetics of Mammographic Appearances and Patterns (The GenMap Study) Completed NCT01160510
45 Vitamin D and Mammographic Breast Density Completed NCT01747720 Not Applicable
46 Histology of Functional Density in Premenopausal Breast Completed NCT01588834
47 Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women Recruiting NCT00445445
48 Histology of Functional Density in Postmenopausal Breast Enrolling by invitation NCT01240278
49 Breast Cancer, Breast Disease, and Pesticides Completed NCT00341315
50 Diffusion Magnetic Resonance Imaging in Mamographically Detected Asymmetric Densities Not yet recruiting NCT03696147

Search NIH Clinical Center for Mammographic Density

Genetic Tests for Mammographic Density

Anatomical Context for Mammographic Density

MalaCards organs/tissues related to Mammographic Density:

41
Breast, Testes, Bone, Brain, Ovary, Pituitary, Prostate

Publications for Mammographic Density

Articles related to Mammographic Density:

(show top 50) (show all 577)
# Title Authors Year
1
A comprehensive tool for measuring mammographic density changes over time. ( 29392583 )
2018
2
Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. ( 29346471 )
2018
3
Should breast cancer screening programs routinely measure mammographic density? ( 29624213 )
2018
4
The origins of breast cancer associated with mammographic density: a testable biological hypothesis. ( 29514672 )
2018
5
Breast cancer risk factors and mammographic density among high-risk women in urban China. ( 29423438 )
2018
6
Automated Volumetric Analysis of Mammographic Density in a Screening Setting: Worse Outcomes for Women with Dense Breasts. ( 29944088 )
2018
7
Prenatal diethylstilbestrol exposure and mammographic density. ( 29658110 )
2018
8
Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study. ( 29671181 )
2018
9
Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer. ( 29190506 )
2018
10
Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds. ( 29884207 )
2018
11
Circulating Hormones and Mammographic Density in Premenopausal Women. ( 29330698 )
2018
12
Alcohol consumption across the life course and mammographic density in premenopausal women. ( 28952004 )
2018
13
Adiposity at Age 10 and Mammographic Density among Premenopausal Women. ( 29500187 )
2018
14
Mammographic Density Distribution in Ras Al Khaimah (RAK): Relationships with Demographic and Reproductive Factors ( 29936786 )
2018
15
Breast Cancer Risk Associations with Digital Mammographic Density by Pixel Brightness Threshold and Mammographic System. ( 29040039 )
2018
16
Mammographic density changes in surgical weight loss-an indication for personalized screening. ( 29743035 )
2018
17
Serum osteoprotegerin levels and mammographic density among high-risk women. ( 29679262 )
2018
18
Occupational exposures and mammographic density in Spanish women. ( 29074552 )
2018
19
Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program. ( 29925631 )
2018
20
Common genetic variation and novel loci associated with volumetric mammographic density. ( 29665850 )
2018
21
Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer. ( 29626240 )
2018
22
A comparison of five methods of measuring mammographic density: a case-control study. ( 29402289 )
2018
23
The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. ( 29566728 )
2018
24
Comparison of subjective and fully automated methods for measuring mammographic density. ( 28565960 )
2018
25
T1 -based sensing of mammographic density using single-sided portable NMR. ( 29399874 )
2018
26
Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. ( 29502324 )
2018
27
An overview of mammographic density and its association with breast cancer. ( 29651637 )
2018
28
Mammographic Density and Circulating Sex Hormones: a Cross-Sectional Study in Postmenopausal Korean Women. ( 30039309 )
2018
29
Physical activity and mammographic density in an Asian multi-ethnic cohort. ( 30062608 )
2018
30
Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study. ( 30092829 )
2018
31
High mammographic density in women is associated with protumor inflammation. ( 30092832 )
2018
32
Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study. ( 30180161 )
2018
33
Regular physical activity and mammographic density: a cohort study. ( 30194548 )
2018
34
Methodological challenges and updated findings from a meta-analysis of the association between mammographic density and breast cancer. ( 30206060 )
2018
35
Mammographic Density Distribution of Healthy Taiwanese Women and its Naturally Decreasing Trend with Age. ( 30297784 )
2018
36
Overeating, caloric restriction and mammographic density in Spanish women. DDM-Spain study. ( 30314562 )
2018
37
Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women. ( 30352839 )
2018
38
Do Birthweight and Weight Gain During Infancy and Early Childhood Explain Variation in Mammographic Density in Women in Midlife? Results From Cohort and Sibling Analyses. ( 30383202 )
2018
39
Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study. ( 30400783 )
2018
40
Milk intake and mammographic density in premenopausal women. ( 30456438 )
2018
41
Mammographic density and breast tissue expression of inflammatory markers, growth factors, and vimentin. ( 30497427 )
2018
42
Predicting interval and screen-detected breast cancers from mammographic density defined by different brightness thresholds. ( 30545395 )
2018
43
Breast compression parameters and mammographic density in the Norwegian Breast Cancer Screening Programme. ( 29098437 )
2017
44
Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. ( 29207971 )
2017
45
Mammographic density and risk of breast cancer by tumor characteristics: a case-control study. ( 29246131 )
2017
46
Alcohol consumption and mammographic density in the Danish Diet, Cancer and Health cohort. ( 28965165 )
2017
47
Mammographic density and other risk factors for breast cancer among women in China. ( 29193600 )
2017
48
Residential particulate matter and distance to roadways in relation to mammographic density: results from the Nurses' Health Studies. ( 29169389 )
2017
49
The Association of Mammographic Density and Molecular Breast Cancer Subtype. ( 28698184 )
2017
50
Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study. ( 28957821 )
2017

Variations for Mammographic Density

Expression for Mammographic Density

Search GEO for disease gene expression data for Mammographic Density.

Pathways for Mammographic Density

Pathways related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1
2
Show member pathways
11.97 CYP19A1 CYP1A1 CYP1B1
3
Show member pathways
11.69 ESR1 PGR PRL
4
Show member pathways
11.58 CYP17A1 CYP19A1 HSD17B1
5
Show member pathways
11.39 COMT CYP17A1 CYP19A1 CYP1A1 HSD17B1
6 11.26 CYP1A1 CYP1B1 ESR1
7
Show member pathways
11.25 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 HSD17B1
8
Show member pathways
11.17 CYP1A1 CYP1B1
9 11.14 CYP1A1 CYP1B1
10
Show member pathways
11.09 COMT CYP19A1 CYP1A1 CYP1B1 HSD17B1
11 11.06 CYP19A1 PGR
12
Show member pathways
10.92 CYP1A1 CYP1B1
13 10.85 IGF1 IGFBP3
14
Show member pathways
10.83 CYP17A1 HSD17B1
15 10.79 CYP17A1 CYP19A1 CYP1A1 CYP1B1 HSD17B1 IGF1
16 10.66 CYP1A1 CYP1B1 ESR1
17 10.13 CYP19A1 HSD17B1
18 10.1 CYP19A1 ESR1 HSD17B1

GO Terms for Mammographic Density

Cellular components related to Mammographic Density according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
2 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.8 CYP17A1 CYP19A1 CYP1A1 CYP1B1 HSD17B1
2 cellular protein metabolic process GO:0044267 9.77 IGF1 IGFBP3 PRL
3 response to lipopolysaccharide GO:0032496 9.74 COMT CYP1A1 PRL
4 response to organic cyclic compound GO:0014070 9.69 COMT CYP1A1 PRL
5 steroid metabolic process GO:0008202 9.67 CYP17A1 CYP1A1 CYP1B1
6 negative regulation of smooth muscle cell proliferation GO:0048662 9.59 COMT IGFBP3
7 regulation of multicellular organism growth GO:0040014 9.58 IGF1 PRL
8 positive regulation of JAK-STAT cascade GO:0046427 9.58 CYP1B1 PRL
9 epoxygenase P450 pathway GO:0019373 9.56 CYP1A1 CYP1B1
10 uterus development GO:0060065 9.55 CYP19A1 ESR1
11 androgen metabolic process GO:0008209 9.54 CYP19A1 ESR1
12 developmental process GO:0032502 9.52 COMT CYP1A1
13 estrogen biosynthetic process GO:0006703 9.48 CYP19A1 HSD17B1
14 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 IGF1 IGFBP3
15 omega-hydroxylase P450 pathway GO:0097267 9.43 CYP1A1 CYP1B1
16 steroid biosynthetic process GO:0006694 9.43 CYP17A1 CYP19A1 HSD17B1
17 toxin metabolic process GO:0009404 9.37 CYP1A1 CYP1B1
18 mammary gland development GO:0030879 9.33 CYP19A1 PGR PRL
19 testosterone biosynthetic process GO:0061370 9.32 CYP19A1 HSD17B1
20 sterol metabolic process GO:0016125 9.13 CYP17A1 CYP19A1 CYP1B1
21 estrogen metabolic process GO:0008210 8.8 COMT CYP1B1 HSD17B1

Molecular functions related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.85 CYP17A1 CYP19A1 CYP1A1 CYP1B1 HSD17B1
2 heme binding GO:0020037 9.71 CYP17A1 CYP19A1 CYP1A1 CYP1B1
3 iron ion binding GO:0005506 9.67 CYP17A1 CYP19A1 CYP1A1 CYP1B1
4 monooxygenase activity GO:0004497 9.61 CYP19A1 CYP1A1 CYP1B1
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.5 CYP19A1 CYP1A1 CYP1B1
6 steroid hydroxylase activity GO:0008395 9.49 CYP19A1 CYP1A1
7 steroid binding GO:0005496 9.43 ESR1 HSD17B1 PGR
8 aromatase activity GO:0070330 9.33 CYP19A1 CYP1A1 CYP1B1
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP17A1 CYP19A1 CYP1A1 CYP1B1
10 oxygen binding GO:0019825 8.92 CYP17A1 CYP19A1 CYP1A1 CYP1B1
11 metal ion binding GO:0046872 10.08 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 ESR1

Sources for Mammographic Density

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....